Discover the Copay Assistance Program

Eligible commercially insured patients may qualify for the Doptelet Copay Assistance Program

What's the program?

Eligible patients may pay as little as $0 for each Doptelet prescription
Annual maximum benefit up to $15,000

Eligible patients must:

Have commercial insurance that covers Doptelet
Not be enrolled in any state or covered by a state or federal healthcare program such as Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD), or TRICARE
Be 18 years of age or older
Be a resident in the United States or a US Territory
Be prescribed Doptelet for an FDA-approved use

How to enroll:

Approved pharmacies, healthcare professionals, and Doptelet Connect can enroll patients
Patients can enroll themselves as well as their caregivers
Please call 1-833-368-2663 Monday–Friday 8 am–8 pm ET for more information

Terms and Conditions

Patients pay as little as $0 per prescription. Copay Assistance Program has an annual calendar cap of $15,000
Patient has an on-label prescription
The Copay Assistance Program is void where prohibited by law, taxes, or restricted
This offer is non-transferable, no substitutions are permissible, and this offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
Sobi, Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice
The Copay Assistance Program for Doptelet is not insurance and is not intended to substitute for insurance
Patients, pharmacists, and healthcare providers must not seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this Copay Assistance Program. Patients must not seek reimbursement from any health savings, flexible spending, or other healthcare reimbursement accounts for the amount of assistance received from the Copay Assistance Program
Certain information pertaining to your use of the Copay Assistance Program will be shared with Sobi, Inc., the sponsor of the Copay Assistance Program. The information disclosed will include the date the prescription is filled, the number of pills or product dispensed by the pharmacists, and the amount of your copay that will be paid for by using this Copay Assistance Program. For more information, please see the Sobi Privacy Policy at https://sobi-northamerica.com/privacy-policy
Acceptance in this Copay Assistance Program is not conditioned on any past, present, or future purchase, including additional doses
Enrollment for the Copay Assistance Program is valid through the calendar year
Sobi reserves the right to change Copay Assistance Program terms at any time

For US healthcare professionals only
Important Safety Information
Prescribing Information
Patient Information Leaflet
For Patients

Questions About Doptelet?

Expand All

Doptelet^® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.¹

Doptelet is a thrombopoietin receptor agonist (TPO-RA) that works with the body to increase platelet production.¹

You may see platelet counts rise in as few as 8 days.¹ To read more about the clinical trials and results for Doptelet, visit our efficacy page.

It is recommended to start all patients with a dosage strength of 20 mg once daily and dose adjust as needed. Please note that 20 mg is the initial dose regimen for all patients except those taking Moderate or Strong Dual Inducers or Moderate or Strong Dual Inhibitors of CYP2C9 and CYP3A4. Depending on your patient’s treatment goal, the dose could be titrated up or down.¹ Refer to the Titration Calculator or the Full Prescribing Information for more details on Titration.

It is recommended that patients take it as soon as they remember, but they should not take 2 doses at one time to make up for a missed dose. It is advised patients take their next Doptelet dose at their usual scheduled time.¹ Refer to the Full Prescribing Information for more information on Doptelet dosing.

Doptelet may affect the way other medications work, and other medications may affect the way Doptelet works. Dose adjustments are recommended for adult patients living with low platelets in chronic ITP taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors.¹ Refer to the Full Prescribing Information to learn more.

Patients should store Doptelet tablets in the original package and at room temperature meaning between 68^oF to 77^oF (20^oC to 25^oC).¹ Please remind patients to store Doptelet, and all medicines, out of the reach of children.

Thrombotic/Thromboembolic Complications: DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic immune thrombocytopenia. Monitor platelet counts. Monitor for signs and symptoms of thromboembolic events and institute treatment promptly.

In clinical trials, the most common adverse reactions, which occurred in 10% or more adults living with low platelets in chronic ITP treated with Doptelet, were: headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.¹ To read more about adverse reactions with Doptelet, visit our safety page.

Doptelet can be taken with any kind of food to help your patients reach their target platelet count. Please note that food is required when taking Doptelet.¹

Yes, the Doptelet Copay Assistance Program is for eligible patients who have commercial prescription insurance. Patients may pay as little as $0 per prescription, up to a maximum of $15,000 per calendar year. Visit the access page to view terms and conditions, and learn more about access and reimbursement support from Doptelet Connect.

Immune thrombocytopenia (ITP) is an immune disorder characterized by low platelet counts (<100×10⁹/L). The mechanisms of ITP can involve both increased platelet destruction and impaired platelet production.²

Common symptoms of immune thrombocytopenia include bruising, petechiae, bleeding, and fatigue.³

Any more questions?

Our support specialists can help answer your questions about Doptelet and access options — call us at
833-368-2663.
Monday–Friday 8 AM–8 PM ET.

References:

1. DOPTELET (avatrombopag) [prescribing information]. Durham, NC: AkaRx, Inc; 2021.
2. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829-2835.
3. NORD (National Organization for Rare Disorders) website: immune thrombocytopenia. Available at: https://rarediseases.org/rare-diseases/immune-thrombocytopenia/. Accessed May 12, 2021.

INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

DOPTELET^® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.

Serious Adverse Reactions

Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).

Adverse Reactions

The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

Postmarketing Experience

Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

For WAC pricing, visit doptelethcp.com/wac-pricing.

INDICATION & IMPORTANT
SAFETY INFORMATION